Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial

نویسندگان

  • Axel Finckh
  • Geraldine M Mc Carthy
  • Anne Madigan
  • Daniel Van Linthoudt
  • Marcel Weber
  • David Neto
  • Georges Rappoport
  • Sandra Blumhardt
  • Diego Kyburz
  • Pierre-Andre Guerne
چکیده

INTRODUCTION Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. METHODS Patients with CPPD arthropathy were randomized to receive either weekly subcutaneous injections of 15 mg/week of MTX or placebo (PBO) for three months, in a double-blind, crossover randomized controlled trial. Inclusion criteria comprised definite CPPD disease, recurrent arthritis or persistent polyarthritis, and an insufficient response to NSAIDs, glucocorticoids or colchicine. The primary outcome was an improvement in the disease activity scores based on 44 joints (DAS44). The analysis was performed on an intent-to-treat basis. RESULTS We randomized 26 patients, and compared 25 treatment periods on MTX with 21 treatment periods on PBO. Baseline characteristics were balanced between the groups. The evolution of the DAS44 was not statistically significantly different between groups (median DAS44 decreased by -0.08 on MTX versus -0.13 on PBO, after three months, P = 0.44). Furthermore, pain levels remained stable in both groups (median change in VAS Pain -1 unit on MTX and 0 on PBO, P = 0.43), and none of the secondary outcomes was significantly different between the two groups. Minor adverse events (AE) did not differ in frequency between the groups, but the only serious AE occurred on MTX (bicytopenia). CONCLUSIONS The results of this trial with MTX in this older population with chronic or recurrent CPPD arthropathy suggest no strong effect of MTX on disease activity. TRIAL REGISTRATION EudraCT No: 2007-003479-37. Registered 26 April 2008.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?

Chronic calcium pyrophosphate crystal arthritis is a clinical consequence of the formation and deposition of these crystals in joints and can result in persistent arthritis. Curative treatment would require the removal of crystals from joints and tissues, but to date all agents tested have proven ineffective. Management of the inflammatory manifestations of chronic calcium pyrophosphate disease...

متن کامل

EULAR recommendations for calcium pyrophosphate deposition. Part II: management.

OBJECTIVES To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD). METHODS A multidisciplinary guideline development group of 15 experts, representing 10 European countries, generated key propositions for management of CPPD using a Delphi consensus approach. For each recommendation research evidence was searched systematically. Whenever possible, t...

متن کامل

Effects of Letrozole Compared with Danazol on Patients with Confirmed Endometriosis: A Randomized Clinical Trial

Background Letrozole is an aromatase inhibitor which can decrease estrogen production in peripheral tissues and endometriosis. Danazol, as an androgen, inhibits estrogen production in ovaries and recently has been introduced as an aromatase inhibitor. This study was designed to compare the effects of Danazol with Letrozole on endometriosis symptom relief. MaterialsAndMethods This study was a ra...

متن کامل

Treatment of Nongout Joint Deposition Diseases: An Update

This update develops the actual therapeutic options in the management of the joint involvement of calcium pyrophosphate deposition disease (CPPD), basic calcium phosphate (BCP) deposition disease, hemochromatosis (HH), ochronosis, oxalosis, and Wilson's disease. Conventional pharmaceutical treatment provides benefits for most diseases. Anti-interleukine-1 (IL-1) treatment could provide similar ...

متن کامل

Do Statins Improve Lung Function in Asthmatic Patients? A Randomized and Double-Blind Trial

      There are evidences that statins have anti-inflammatory effects beyond their cholesterol lowering properties. The study was conducted to assess the effects of atorvastatin on asthma as an inflammatory disease. Patients with moderate to severe asthma were entered this randomized, double blind, crossover clinical trial. The impact of oral atorvastatin (10 mg/day) on the lung function of nor...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 16  شماره 

صفحات  -

تاریخ انتشار 2014